Liraglutide: Reference Overview and Reconstitution Notes

Liraglutide is a GLP-1 receptor agonist (a molecule that activates a specific protein receptor) in the metabolic and weight-regulation category. It has been FDA-approved for certain specific uses.

Liraglutide

What it is

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In plain terms, a receptor agonist is a molecule that fits into a specific "slot" (called a receptor) on a cell and switches it on, much like a key turning a lock. GLP-1 is a natural signal the body produces after eating.

Liraglutide is built from a chain of about 31 amino acids (amino acids are the small building blocks that link together to form proteins). Its total molecular weight is about 3,751 Da (Da stands for dalton, a tiny unit scientists use to measure how heavy a molecule is). What makes liraglutide stand out is a short fatty-acid "tail" (a small grease-like chain, called palmitoyl) attached to its side. This tail allows the molecule to grip loosely onto albumin (a common protein found in blood), which slows it from being broken apart. Think of it like a magnet: the fatty tail clings to albumin just enough to keep the molecule stable and active for longer.

Research context and categorization

Liraglutide falls under the metabolic and weight-regulation category of peptides. As a GLP-1 receptor agonist, it is often studied in connection with how the body manages blood sugar, hunger signals, and body weight. It belongs to a broader family of molecules called incretins (natural gut signals that help control blood sugar after meals).

In research and clinical literature, liraglutide has been studied for blood sugar control in type 2 diabetes, for long-term weight management, and for heart-health outcomes. Liraglutide is one of the FDA-approved members of the GLP-1 class for certain specific uses. Those approved uses apply to finished drug products. Any use of research-grade material, or any use outside the approved conditions, is investigational and not a confirmed or approved benefit.

Status

• Regulatory status: FDA-approved for specific uses. Liraglutide is the active ingredient in approved products for type 2 diabetes blood sugar control (first approved in 2010, with a later approval related to heart risk reduction in certain patients) and for long-term weight management (first approved in 2014, later extended to certain adolescents). Material sold for laboratory use is labeled research-only, is not an approved drug product, and is not for human or animal use.
• Sport status: Not specifically listed on the WADA Prohibited List (the official list of substances banned in competitive sport). GLP-1 receptor agonists as a class have drawn attention from WADA, and some related compounds in the class have appeared on the WADA Monitoring Program, but liraglutide is not named as a prohibited substance on the current List. The List is updated each year, so anyone competing under anti-doping rules should check the current List and any sport-specific policy directly.

Reconstitution notes (general)

Research-grade liraglutide typically comes as a lyophilized (freeze-dried) powder. Before lab use, it must be reconstituted, meaning mixed with bacteriostatic water (sterile water with a small amount of preservative added) to turn the powder back into a liquid solution.

The concentration you get equals the milligrams of powder in the vial divided by the milliliters of water you add. For example, 5 mg of powder mixed with 2 mL of water gives a solution of 2.5 mg/mL. Adjust the amount of water to reach the working concentration you need, and use the peptide calculator to check the math.

Dilution and handling notes (compound-specific)

Key point: Liraglutide is very sensitive to pH levels and physical agitation. Its ability to dissolve drops sharply below a neutral pH, which can make reconstituted research solutions look cloudy.

Liraglutide is one of the more formulation-sensitive GLP-1 peptides. Its behavior is driven largely by that fatty-acid tail described above. One important distinction: the commercial finished drug product ships as a ready-to-use liquid in prefilled pens, formulated at a higher pH (around pH 8) because liraglutide dissolves much better under mildly alkaline (non-acidic) conditions. pH is a scale from 0 to 14 that measures how acidic or basic a liquid is. A pH of 7 is neutral (like pure water), below 7 is acidic, and above 7 is alkaline.

If you are working with liraglutide as a lyophilized powder, it is research-supply material rather than the finished drug, and the points below apply.

Solubility and Handling Properties

• pH-dependent solubility: Liraglutide dissolves well under mildly alkaline conditions, but its solubility drops sharply below roughly neutral pH, reaching a low point around pH 4 to 5. Standard bacteriostatic water (0.9% benzyl alcohol) sits near neutral pH, so concentrated preparations can look hazy or cloudy. This haziness reflects a natural property of the molecule and is not necessarily a sign that it has degraded.
• Self-association: The fatty-acid tail causes liraglutide molecules to cluster together into small groups, similar to how soap molecules clump together in water. The degree of clustering shifts with concentration and pH near neutral, so the appearance of the solution can vary between preparations.
• Aggregation under mechanical stress: Shaking the vial hard can push molecules to clump into larger, unwanted aggregates (think of lint sticking together) and can also cause foaming. The fatty-acid tail makes foaming worse. The fix is straightforward: add the water slowly down the inside wall of the vial, then swirl or gently roll it instead of shaking.
• Working concentration: Because solubility is limited, more dilute solutions tend to stay clearer and easier to handle than very concentrated ones. Choose a water volume that keeps the solution manageable rather than pushing all the powder into a very small volume. Divide the solution into small working portions (called aliquots) to cut down on the number of freeze-thaw cycles.

Handling and storage

Store reconstituted solution in the refrigerator at 2 to 8 C and keep it away from direct light. Wipe the vial stopper with an alcohol swab before each use, and write the reconstitution (mix) date on the vial label. A reconstituted peptide solution is generally treated as having about a four-week working window when kept refrigerated.

Discard the solution if it changes color, develops floating particles, or turns cloudy in a way that does not clear up. With liraglutide, keep in mind that a faint haze can be normal due to its pH-dependent solubility. Judge appearance together with how old the solution is, rather than basing the decision on cloudiness alone.

Related reading

• Melanotan I
• Oxytocin
• Semaglutide
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is the molecular weight and structure of liraglutide?

Liraglutide is a ~31-amino-acid peptide with a molecular weight of approximately 3,751 Da. A palmitoyl fatty-acid tail is attached to its side chain, allowing loose binding to albumin, which slows enzymatic breakdown and extends molecular stability.

How is research-grade liraglutide reconstituted?

Research-grade liraglutide arrives as lyophilized (freeze-dried) powder. It is reconstituted by adding bacteriostatic water; the resulting concentration equals milligrams of powder divided by milliliters of water added (mg/mL).

Is liraglutide prohibited by WADA for competitive athletes?

Liraglutide is not currently named as a prohibited substance on the WADA Prohibited List. The list is updated annually and some GLP-1 class compounds appear on the WADA Monitoring Program, so competitors should verify the current list directly.

What the research community gets wrong about liraglutide handling

Liraglutide is one of the fussier GLP-1 peptides to reconstitute, and a few habits carried over from easier compounds tend to cause trouble. Here is what trips people up at the bench.

• Reading haze as spoilage. A cloudy look in a concentrated preparation is often just liraglutide's pH-dependent solubility showing itself, not proof the peptide has broken down. Its solubility falls sharply below roughly neutral pH, and plain bacteriostatic water sits near neutral, so a faint haze can be normal. Judge the solution by its age and by whether particles settle out, not by cloudiness alone.
• Expecting research powder to act like the pen. The finished commercial product is a buffered liquid held at about pH 8, where liraglutide dissolves much better. Lyophilized research-supply powder mixed with near-neutral water is a different situation, so do not assume it will look glass-clear the way a prefilled pen does.
• Shaking to speed things up. The fatty-acid tail makes liraglutide foam easily and clump into unwanted aggregates when it is knocked around. Add water slowly down the inside wall of the vial and swirl or gently roll it. Do not shake.
• Assuming the molecules stay separate. Liraglutide self-associates into small clusters, and lab studies point to a heptamer (a group of seven) as a stable form in solution. Because clustering shifts with concentration and pH, the appearance can vary between preparations, so treat batch-to-batch differences in clarity as expected rather than as a defect.
• Freezing the working stock. The manufacturer label for the finished drug says not to freeze it, and freeze-thaw cycles add physical stress that peptides handle poorly. Keep reconstituted solution refrigerated at 2 to 8 C, split it into small working portions, and avoid repeated freezing and thawing.

From our bench: when we reconstitute liraglutide powder with plain bacteriostatic water, we pay attention to when the haze shows up and whether it moves. A faint cloudiness that appears at higher concentration and holds steady behaves differently from particles that drift or settle over the next day. Note the water volume you chose so you can line up clarity across your own preparations and tell a solubility haze apart from something that is actually changing.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem, Liraglutide (CID 16134956), formula C172H265N43O51 , National Library of Medicine
5. VICTOZA (liraglutide) injection label , FDA/DailyMed (solution pH ~8.15, phosphate buffer, store 2-8 C, do not freeze)
6. Frederiksen et al., Oligomerization of a Glucagon-like Peptide 1 Analog, Biophysical Journal 2015 (liraglutide heptamers). PMID 26340816